These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34918381)

  • 1. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.
    Ke Q; Shi C; Lv Y; Wang L; Luo J; Jiang L; Yang J; Zhou Y
    FASEB J; 2022 Jan; 36(1):e22078. PubMed ID: 34918381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
    Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
    Chang YK; Choi H; Jeong JY; Na KR; Lee KW; Lim BJ; Choi DE
    PLoS One; 2016; 11(7):e0158810. PubMed ID: 27391020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE
    Leng W; Ouyang X; Lei X; Wu M; Chen L; Wu Q; Deng W; Liang Z
    Mediators Inflamm; 2016; 2016():6305735. PubMed ID: 28104929
    [No Abstract]   [Full Text] [Related]  

  • 7. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
    Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
    Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus.
    Birnbaum Y; Chen H; Tran D; Nylander S; Ye Y
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):829-840. PubMed ID: 34232433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation.
    Li S; Lin Q; Shao X; Mou S; Gu L; Wang L; Zhang Z; Shen J; Zhou Y; Qi C; Jin H; Pang H; Ni Z
    Exp Cell Res; 2019 Oct; 383(1):111488. PubMed ID: 31276670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin Ameliorates Ovulation Disorders via Attenuating Activated Microglia-Mediated Hypothalamic Inflammation in HFD-Fed Mice.
    Chen X; Xiao Z; Liu Q; Luo D; Cai Y; Fan M
    Neuroendocrinology; 2024; 114(4):331-347. PubMed ID: 38147832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
    Gordon M; Meagher P; Connelly KA
    Can J Diabetes; 2021 Aug; 45(6):553-556. PubMed ID: 33388277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH
    Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation.
    Hooftman A; Angiari S; Hester S; Corcoran SE; Runtsch MC; Ling C; Ruzek MC; Slivka PF; McGettrick AF; Banahan K; Hughes MM; Irvine AD; Fischer R; O'Neill LAJ
    Cell Metab; 2020 Sep; 32(3):468-478.e7. PubMed ID: 32791101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk Among NLRP3 Inflammasome, ET
    Muhammad RN; Ahmed LA; Abdul Salam RM; Ahmed KA; Attia AS
    Neurotherapeutics; 2021 Oct; 18(4):2664-2681. PubMed ID: 34664178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy.
    Hu H; Li W; Hao Y; Peng Z; Zou Z; Wei J; Zhou Y; Liang W; Cao Y
    Cell Rep Med; 2024 Aug; 5(8):101690. PubMed ID: 39168099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
    Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS
    Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.